SCHEMBL5663604

SCHEMBL5663604

CCOC(Cc1ccc(NCCCN2CCc3ccccc32)cc1)C(=O)OC(=O)[C@@H](N)CCCNC(=N)N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.38
NPY4R P50391 7/20 0.33
NPY1R P25929 5/20 0.33
LMNA P02545 1/20 0.33
NPY2R P49146 4/20 0.32
NPY5R Q15761 4/20 0.32
KDM4E B2RXH2 2/20 0.32
POLB P06746 2/20 0.32
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PPARA Q07869 3/20 0.32
AVPR2 P30518 2/20 0.32
TNF P01375 1/20 0.32
NPC1 O15118 1/20 0.31
TP53 P04637 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL5663601 0.91 PPARG (0.46) PPARGPPARA
Arginine SCHEMBL5663597 0.91 PPARG (0.46) PPARGPPARA
SCHEMBL6675473 0.88 MAPT (0.37) NPY4RNPY1RLMNAKDM4EPOLB
SCHEMBL4826323 0.88 PPARG (0.37) PPARGNPY4RNPY1RLMNANPY2R
SCHEMBL4824348 0.84 PPARG (0.38) PPARGNPY4RNPY1RLMNANPY2R
SCHEMBL5662331 0.83 PPARG (0.47) PPARGKDM4EPOLBGAAMEN1
SCHEMBL4825272 0.82 NPY4R (0.32) NPY4RNPY1RNPY2RNPY5RRORC
SCHEMBL4823696 0.82 NPY4R (0.32) NPY4RNPY1RNPY2RNPY5RRORC
SCHEMBL5662336 0.81 MAPK1 (0.35) NPY4RNPY1RMEN1KMT2ANPC1
SCHEMBL4824935 0.81 TSHR (0.34) PPARGLMNAGAAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S LABORATORIES LIMITED (IN) 2007-04-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093476-A1 Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them GPR119, NR1H3, NR1H2 PPARG 170/4885NPY4R 26/4885NPY1R 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.